Amphetamine Stimulant denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for amphetamine stimulant are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Step Therapy for Amphetamine Stimulants — and How to Appeal

Step therapy ("fail-first") requirements for amphetamine stimulants mean that UnitedHealthcare requires documented evidence that the patient has tried one or more alternative ADHD medications — typically from a different stimulant class or a non-stimulant agent — before it will authorize the requested amphetamine-based product. This policy is designed to encourage use of lower-cost formulary alternatives, but it regularly creates barriers for patients who have already failed those alternatives, or for whom a step-therapy protocol is clinically inappropriate based on their history or comorbidities.

Step-therapy denials are among the most frequently overturned on appeal, because the clinical evidence needed — prior medication trials with documented outcomes — almost always exists in the treating provider's records.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503): You are entitled to a full-and-fair review. The plan must provide the specific step-therapy criteria it applied and allow submission of clinical evidence demonstrating that the required steps were completed or that an override is warranted.
• External review (ACA §2719): If the internal appeal is upheld, file for independent external review within the window stated in your denial letter (typically approximately 180 days from the final internal denial). The IRO applies recognized clinical standards independently.
• Expedited review: If the treatment gap creates an urgent clinical risk, request expedited review. Plans typically must respond within 72 hours.
• State step-therapy override laws: Many states require insurers to grant step-therapy overrides when a patient has already tried and failed the required steps, when the required steps are contraindicated, or when the patient is stable on their current regimen. Check whether your state law applies to your plan type (state laws cover fully-insured plans; self-funded ERISA plans may only be subject to federal standards).

## Documentation to Gather

1. Step-therapy trial history — A complete chronological record of every ADHD medication tried, including the dates of initiation and discontinuation, the clinical response, and the documented reason each was inadequate (ineffective, not tolerated, or otherwise inappropriate). 2. Prescriber step-therapy override letter — A letter from the treating physician stating that the required steps have been completed, or explaining why they are clinically inappropriate for this patient, with specific reference to chart findings. 3. Diagnosis confirmation — Documentation of the diagnostic evaluation supporting the ADHD diagnosis and the clinical rationale for stimulant therapy. 4. Current stability documentation (if applicable) — If the patient is currently stable on the amphetamine stimulant (e.g., following a prior authorization that lapsed), include records demonstrating that disrupting treatment would cause harm. 5. Applicable clinical guideline organization reference — The prescriber should note the relevant professional body (e.g., American Academy of Pediatrics, American Psychiatric Association) that recognizes the clinical appropriateness of the requested medication after failure of alternatives.

## Criteria-Mapping Strategy

Obtain UHC's step-therapy policy and list each required step. For each one, provide a chart-sourced response confirming it was completed — or the clinical justification for why it was bypassed. A structured, criterion-by-criterion submission is significantly more effective than a general narrative, and it forces the reviewer to engage with each piece of evidence individually rather than issuing a blanket uphold.